Pregnancy, Privacy, Procedural Risk: JAAD Sets Nov 2026 Review

Pregnancy, patient privacy, and procedural risk converge in a single peer-reviewed piece slated for the November 2026 issue of the Journal of the American Academy of Dermatology (Volume 95, Issue 5).

The forthcoming article — authored by Hazel Seohyun Lee and Deshan F. Sebaratnam — takes its title from those three pillars and signals a deliberately structured review of how dermatologists manage patients at the intersection of reproductive status, data confidentiality, and procedural decision-making.

What does the triadic framing suggest?

The title's structure — pregnancy, privacy, procedural risk — reads as an argument that these three concerns belong in the same workflow. Pregnant patients present routinely to dermatology clinics. Topical and systemic agents carry varying teratogenic profiles. Procedures from shave biopsies to energy-based interventions require modified consent scripts and risk-counseling language. Privacy considerations — for adolescents, surrogate decision-makers, and sensitive diagnoses — layer onto every clinical encounter.

Bundling the themes in one review implies the authors treat them as connected problems rather than three independent topics. A clinic that handles pregnancy-aware prescribing well but documents consent poorly, or protects chart-level privacy but skips pregnancy-specific procedural counseling, would still fall short under this framing.

What the metadata tells us, and what it doesn't

The available publication record names the authors, journal, volume, issue, and publication month. It does not specify article type — narrative review, systematic review, case series, or editorial commentary — word count, or specific clinical recommendations.

Readers seeking conclusions about particular medications, devices, or consent templates will need to wait for the full text. What the metadata does establish is the venue: JAAD, the field's flagship peer-reviewed journal. The journal's selection of this triadic review signals that editors consider the intersection worth consolidating for a wide clinical readership.

What changes for practicing dermatologists today?

Nothing immediately — the article hasn't shipped yet. A clinician's practical question — do I need to revise my consent forms or prescribing protocols now? — has a straightforward answer: not yet. But put the November 2026 publication on the reading list for any practice that sees reproductive-age patients.

In the meantime, clinics can use the article's three-pillar structure as a self-audit:

• Pregnancy-aware prescribing — review teratogenic profiles of agents commonly prescribed in your panel
• Privacy documentation — chart language, chaperone policies, adolescent consent workflows
• Procedural risk counseling — what patients hear before biopsies, excisions, and energy-based procedures during pregnancy

Forward look

The November 2026 issue sits roughly a year out from the current publication cycle. Expect downstream activity once the article lands: correspondence in JAAD Case Reports, possible position statements from dermatology societies, and likely a dedicated session at a major dermatology meeting in 2027. Lee and Sebaratnam have staked out a framework; the field's response will decide whether it becomes a clinical standard or stays a single review.